Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lancet urges EC approval

This article was originally published in The Tan Sheet

Executive Summary

Acting FDA Commissioner Andrew von Eschenbach, MD, should take an independent stand in the face of political pressure and approve Barr Pharmaceuticals Rx-to-OTC switch application for Plan B emergency contraceptive, according to an editorial in The Lancet May 20. "Von Eschenbach should move quickly to approve Plan B to show he has the independence needed to be an effective leader of the FDA," the British journal states. FDA has been "stalling" on issuing a decision for the emergency contraceptive for over a year, "apparently to avoid offending antiabortion supporters of President Bush, who claim that the contraceptive is an abortifacient," the piece asserts...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts